MAPT and supranuclear palsy, progressive, 1: Surprisingly, a recent study revealed that individuals with FTLD-TDP-43 type A with combined pathology—encompassing hippocampal sclerosis, Alzheimer’s disease-neuropathologic change (ADNC) (sometimes with co-occurring FTLD-tau/PSP), vascular disease, motor neuron disease, and mammillary body atrophy, ranked from highest to lowest prevalence—showed significantly longer lifespans and longer disease durations than those with only FTLD-TDP-43 type A [1].